U.S. Stock Market Midday Update

Universe Pharmaceuticals fell 10.26%, with increased trading volume and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Stocks with High Trading Volume in the Industry

Eli Lilly fell 1.09%, with a trading volume of $1.245 billion. Based on recent key news:

1. On August 5, Eli Lilly announced its second-quarter financial report, with revenue increasing by 48% year-on-year to $22.97 billion, significantly exceeding market expectations. The net profit was $7.1 billion, and the adjusted earnings per share were $8.38, far surpassing analyst expectations. After the financial report was released, Eli Lilly's stock price rose about 4% in pre-market trading.

2. On August 5, Eli Lilly announced an additional investment of $4.5 billion to expand its production facilities to meet the growing market demand for GLP-1 weight loss drugs. This move further enhances investors' confidence in the company's future growth.

3. On August 6, Morgan Stanley raised Eli Lilly's target stock price from $1,347 to $1,419, reflecting analysts' optimistic expectations for the company's future performance. The pharmaceutical industry is experiencing strong demand and policy support.

Pfizer rose 1.09%, with active trading. Based on recent key news:

1. On August 5, Pfizer director Mortimer J. Buckley purchased 37,632 shares of common stock, showing confidence in the company's future, which may have boosted market sentiment. Source: EDGAR

2. On August 5, Pfizer announced the research and development progress of its oral weight loss drug YP05002. Although no research resources have been invested yet, the market remains attentive to its potential. Source: Pfizer official website

3. On August 5, Pfizer's second-quarter financial report showed strong growth in non-COVID revenues, and the full-year revenue guidance was raised, enhancing investor confidence. Source: Financial report conference call. The pharmaceutical industry faces risks from patent cliffs and rising R&D expenditures.

Merck fell 5.46%, with increased trading volume. Based on recent key news:

1. On August 6, Merck lowered its financial guidance for 2026, expecting adjusted earnings per share of $6.15 to $6.25, below market expectations. This news led to a decline in investor confidence and a drop in stock price. Source: Reuters

2. On August 6, Merck's second-quarter revenue was $2.47 billion, below analysts' expectations of $2.5 billion, raising concerns about its profitability. Source: LSEG

3. On August 7, analysts lowered Merck's target price to $90, reflecting the market's cautious attitude towards its future growth. Source: FactSet. Industry competition is intensifying, and market expectations are being downgraded.

Stocks with High Market Capitalization in the Industry

Johnson & Johnson fell 0.21%, with increased trading volume. Based on recent key news:

1. On August 6, Johnson & Johnson announced its second-quarter financial report for the 2026 fiscal year. Despite strong performance in its innovative pharmaceuticals business, the medical devices and instruments business underperformed expectations, leading to a decline in stock price In the second quarter, revenue was $25.3 billion, a year-on-year increase of 6.6%, with adjusted earnings per share of $2.90. Source: Youyanalysis

2. On August 5, Citi analyst Joanne Wuensch maintained a buy rating on Johnson & Johnson, but Bank of America Securities reiterated a hold rating on July 28, indicating a divergence in market views on Johnson & Johnson. Source: TipRanks

3. On August 4, Johnson & Johnson will speak at the Wells Fargo Healthcare Conference on September 9, 2026, with the market full of expectations for its future development. Source: Business Wire The medical device business performance is weak, affecting the stock price